MBRX Moleculin Biotech, Inc. Stock Quote

MBRX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.64	Insider Own	2.15%	Shs Outstand	28.58M	Perf Week	5.65%
Market Cap	36.90M	Forward P/E	-	EPS next Y	-1.17	Insider Trans	0.00%	Shs Float	27.96M	Perf Month	-28.02%
Income	-18.30M	PEG	-	EPS next Q	-0.25	Inst Own	14.30%	Short Float	1.08%	Perf Quarter	-3.68%
Sales	-	P/S	-	EPS this Y	66.50%	Inst Trans	-1.52%	Short Ratio	2.94	Perf Half Y	-39.63%
Book/sh	2.54	P/B	0.52	EPS next Y	-14.70%	ROA	-21.20%	Target Price	12.39	Perf Year	-64.01%
Cash/sh	2.35	P/C	0.56	EPS next 5Y	-	ROE	-23.10%	52W Range	1.02 - 3.99	Perf YTD	-29.57%
Dividend	-	P/FCF	-	EPS past 5Y	24.40%	ROI	-	52W High	-65.66%	Beta	1.88
Dividend %	-	Quick Ratio	13.90	Sales past 5Y	-	Gross Margin	-	52W Low	34.31%	ATR	0.12
Employees	13	Current Ratio	13.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.32	Volatility	9.17% 8.62%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-17.90%	Profit Margin	-	Rel Volume	0.25	Prev Close	1.31
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	102.44K	Price	1.37
Recom	1.70	SMA20	-4.79%	SMA50	-14.85%	SMA200	-34.68%	Volume	7,023	Change	4.58%

May-19-22 08:05AM	Moleculin to Present at the H.C. Wainwright Global Investment Conference PR Newswire
May-12-22 08:35AM	Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update PR Newswire
May-10-22 08:35AM	Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 PR Newswire
May-05-22 08:15AM	Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire
May-04-22 08:15AM	Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer PR Newswire -5.49%
Apr-21-22 08:47AM	Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma PR Newswire
Apr-14-22 08:05AM	Moleculin Announces Corporate Rebranding and Launch of New Website PR Newswire
Apr-11-22 07:05AM	/C O R R E C T I O N -- Moleculin Biotech, Inc./ PR Newswire
Apr-08-22 01:05PM	Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting PR Newswire
Mar-25-22 07:05AM	Moleculin Reports Full Year Financial Results and Provides Programs Update PR Newswire
Mar-23-22 08:05AM	Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest PR Newswire
Mar-11-22 08:05AM	Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference PR Newswire
Mar-01-22 08:35AM	Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors PR Newswire
Feb-14-22 02:10PM	Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study Benzinga
09:05AM	Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development PR Newswire
Feb-01-22 09:11AM	Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth Simply Wall St.
Jan-20-22 08:40AM	Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference PR Newswire
Jan-18-22 08:05AM	Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma PR Newswire
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th ACCESSWIRE
Jan-07-22 08:30AM	Moleculin to Present at the H.C. Wainwright BioConnect Conference PR Newswire
Dec-27-21 08:05AM	Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire -8.87%
Dec-01-21 08:35AM	Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire +5.80%
Nov-12-21 08:05AM	Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event PR Newswire
Nov-11-21 08:05AM	Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update PR Newswire
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th ACCESSWIRE
Oct-20-21 05:46PM	Houston biotech cos. begin clinical trials for cancer, Covid-19 treatments American City Business Journals
Oct-19-21 09:05AM	Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 PR Newswire
Oct-18-21 08:25AM	Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire
Sep-27-21 07:05AM	Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire
Sep-17-21 08:05AM	Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit PR Newswire +5.42%
Sep-08-21 08:00AM	Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
Aug-12-21 08:18AM	Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update PR Newswire
Aug-03-21 06:29AM	We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate Simply Wall St.
Jul-13-21 08:35AM	Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia PR Newswire
Jun-22-21 08:30AM	CO2 GRO Inc. Announces a CAD $65,500 Commercial Installation Agreement with a Canadian Licensed Producer ACCESSWIRE
Jun-21-21 08:35AM	Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases PR Newswire
Jun-15-21 09:05AM	Moleculin Announces Inclusion in the Russell 2000® Index PR Newswire
May-25-21 11:23AM	Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients Benzinga
09:05AM	Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases PR Newswire
May-12-21 07:35AM	Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update PR Newswire
May-11-21 08:05AM	Moleculin Biotech to Present at the Q2 Virtual Investor Summit PR Newswire
07:30AM	WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate GlobeNewswire
Apr-14-21 09:38AM	Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor Benzinga
07:35AM	Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma PR Newswire
Apr-06-21 07:30AM	Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial PR Newswire
Mar-30-21 07:30AM	Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases PR Newswire +14.86%
Mar-24-21 07:30AM	Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020 PR Newswire
Mar-09-21 07:30AM	Moleculin to Participate in Four Upcoming Healthcare Conferences PR Newswire
Feb-10-21 04:15PM	Moleculin Announces Full Exercise of Over-Allotment Option PR Newswire +7.42%
Feb-08-21 07:30AM	Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases PR Newswire
Feb-05-21 07:30AM	WPD Pharmaceuticals Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug GlobeNewswire
Feb-04-21 03:24AM	What You Need To Know About Moleculin Biotech, Inc.'s (NASDAQ:MBRX) Investor Composition Simply Wall St.
Feb-03-21 08:30AM	Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering PR Newswire -26.76%
Feb-02-21 04:22PM	Moleculin Announces Proposed Underwritten Public Offering PR Newswire +35.96%
07:30AM	Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model PR Newswire
Feb-01-21 07:30AM	Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial PR Newswire -5.45%
Jan-29-21 09:15AM	Moleculin Announces Reverse Stock Split PR Newswire -14.59%
Jan-12-21 10:40AM	Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5% Zacks -5.88%
Jan-07-21 07:30AM	Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire
Dec-29-20 07:30AM	Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas PR Newswire -6.01%
Dec-17-20 07:30AM	Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases PR Newswire
Dec-03-20 07:30AM	Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference PR Newswire
Dec-01-20 07:30AM	Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066 PR Newswire +26.92%
Nov-19-20 07:30AM	Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML PR Newswire +9.06%
Nov-13-20 07:30AM	Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020 PR Newswire +8.31%
Oct-29-20 07:30AM	Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19 PR Newswire
Oct-27-20 07:30AM	Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event PR Newswire
Oct-21-20 07:30AM	Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors PR Newswire
Oct-13-20 07:30AM	Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial PR Newswire
Oct-06-20 07:30AM	Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV PR Newswire
Oct-05-20 07:30AM	Moleculin Appoints Elizabeth Cermak to Board of Directors PR Newswire
Oct-01-20 07:30AM	Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University PR Newswire
Sep-29-20 07:30AM	Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites PR Newswire
Sep-14-20 07:30AM	Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122 PR Newswire +5.32%
Sep-10-20 07:30AM	Moleculin to Present at Upcoming Healthcare Investor Conferences PR Newswire
Sep-09-20 01:52PM	BRK Extends its Footprint into Europe and CIS and "EV" Vehicles with Key Appointment PR Newswire
07:30AM	Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA PR Newswire
Aug-27-20 07:30AM	Moleculin to Present at LD Micro 500 Virtual Investor Conference PR Newswire
Aug-12-20 07:30AM	Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020 PR Newswire -7.95%
Aug-11-20 09:13AM	Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation Simply Wall St.
Jul-21-20 09:59AM	Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment SmarterAnalyst +20.91%
09:36AM	Moleculin Shares Jump on Progress With Virus-Drug Candidate TheStreet.com
07:46AM	Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment MarketWatch
07:30AM	Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus PR Newswire
Jul-16-20 11:11AM	Moleculin Surges on Manufacturing Deal for Coronavirus Therapy Zacks
Jul-15-20 07:30AM	Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate PR Newswire +36.31%
Jul-03-20 11:30AM	Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year? Zacks
Jul-02-20 07:30AM	Moleculin Provides Update on Annamycin Clinical Development PR Newswire
Jul-01-20 05:50PM	Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know Zacks
07:30AM	New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model PR Newswire
Jun-30-20 09:00AM	INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Moleculin Biotech, Inc. for Potential Breach of Fiduciary Duty Claims ACCESSWIRE
Jun-29-20 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
Jun-25-20 07:30AM	Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases PR Newswire
Jun-23-20 08:49AM	Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020 GlobeNewswire
07:30AM	Moleculin to Present at the Life Sciences Investor Forum PR Newswire
Jun-17-20 11:30AM	Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-16-20 07:30AM	Moleculin Announces Confirmatory In Vitro Analysis of WP1122 PR Newswire
Jun-04-20 07:30AM	Moleculin Announces Submission to Expand Clinical Sites in European AML Trial PR Newswire
Jun-02-20 07:30AM	Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment PR Newswire
Jun-01-20 11:30AM	Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year? Zacks +6.42%

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience